Clinical uses of recombinant human thyrotropin

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 12, 2004, Pages 2503-2514

  Gourgiotis, Loukas ^a   Skarulis, Monica C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Multinodular goiter; Recombinant human thyrotropin; Thyroglobulin; Thyroid cancer; Thyroid reserve

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; FLUORODEOXYGLUCOSE F 18; IMMUNOMODULATING AGENT; INTERFERON; IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; HEADACHE; HORMONE INHIBITION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; NAUSEA; NODULAR GOITER; NONHUMAN; PATIENT CARE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THYROID CANCER; WHOLE BODY SCINTISCANNING;

EXPERT TESTIMONY; GOITER; HUMANS; IODINE RADIOISOTOPES; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN;

EID: 10644261447     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.12.2503     Document Type: Review

References (83)

1. ROBBINS J: Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid(1999) 9(5):451-453.
2. EMERSON CH, TORRES MS: Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses. BioDrugs (2003) 17(1):19-38.
3. KACSOH B: The hypothalamohypophyseal system. In: Molecular Endocrinology. McGraw-Hill Companies, Inc., New York, USA (2000):278-279.
4. BECK-PECCOZ P, PERSANI L: Variable biological activity of thyroid-stimulating hormone. Eur. J. Endocrinol. (1994) 131 4):331-340.
5. SCHAAF L, LEIPRECHT A, SAJI M, HUBNER U, USADEL KH, KOHN LD: Glycosylation variants of human TSH selectively activate signal transduction pathways. Mol. Cell. Endocrinol. (1997) 132 1-2):185-194.
6. COLE ES, LEE K, LAUZIERE K et al.: Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology (NY) (1993) 11(9):1014-1024.
7. SZKUDLINSKI MW, THOTAKURA NR, TROPEA JE, GROSSMANN M, WEINTRAUB BD: Asparagine-linked oligosaccharide structures determine clearance and organ distribution of pituitary and recombinant thyrotropin. Endocrinology (1995) 136(8):3325-3330.
8. THOTAKURA NR, DESAI RK, BATES LG, COLE ES, PRATT BM, WEINTRAUB BD: Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology (1991) 128(1):341-348.
9. SZKUDLINSKI MW, GROSSMANN M, LEITOLF H, WEINTRAUB BD: Human thyroid-stimulating hormone: structure-function analysis. Methods (2000) 21(1):67-81.
10. EAST-PALMER J, SZKUDLINSKI MW, LEE J, THOTAKURA NR, WEINTRAUB BD: A novel, nonradioactive in vivo bioassay of thyrotropin (TSH). Thyroid (1995) 5(1):55-59.
11. BRAVERMAN LE, PRATT BM, EBNER S, LONGCOPE C: Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the rhesus monkey. J. Clin. Endocrinol. Metab. (1992) 74(5):1135-1139.
12. RAMIREZ L, BRAVERMAN LE, WHITE B, EMERSON CH: Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J. Clin. Endocrinol. Metab. (1997) 82(9 ):2836-2839.
13. TORRES MS, RAMIREZ L, SIMKIN PH, BRAVERMAN LE, EMERSON CH: Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J. Clin. Endocrinol. Metab. (2001) 86(4):1660-1664.
14. TAIEB D, JACOB T, ZOTIAN E, MUNDLER O: Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid(2004) 14(6):465-467.
15. SHERMAN SI: Thyroid carcinoma. Lancet (2003) 361 9356):501-511.
16. MAZZAFERRI EL: An overview of the management of papillary and follicular thyroid carcinoma. Thyroid (1999) 9(5):421-427.
17. MAZZAFERRI EL: NCCN thyroid carcinoma practice guidelines. Oncology (1999) 13:391-442.
18. BENUA R, SONENBERG M, LEEPER R, RAWSON R: An 18 year study of the use of beef thyrotropin to increase I-131 uptake in metastatic thyroid cancer. J. Nucl. Med. (1964) 5:796-801.
19. MELMED S, HARADA A, HERSHMAN JM, KRISHNAMURTHY GT, BLAHD WH: Neutralizing antibodies to bovine thyrotropin in immunized patients with thyroid cancer. J. Clin. Endocrinol. Metab. (1980) 51 2):358-363.
20. KIRKPATRICK CH, MEEK JC, RICH RR: Mechanism of allergy to components of commercial bovine thyrotropin. J. Allergy Clin. Immunol. (1973) 51(5):296-302.
21. DOW KH, FERRELL BR, ANELLO C: Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid (1997) 7(4):613-619.
22. MEIER CA, BRAVERMAN LE, EBNER SA et al.: Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II study). J. Clin. Endocrinol. Metab. (1994) 78 1):188-196.
23. LADENSON PW, BRAVERMAN LE, MAZZAFERRI EL et al.: Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. (1997) 337 13):888-896.
24. HAUGEN BR, PACINI F, REINERS C et al.: A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. (1999) 84(11):3877-3885.
25. PARK HM, PERKINS OW, EDMONDSON JW, SCHNUTE RB, MANATUNGA A: Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid(1994) 4(1):49-54.
26. PINEDA JD, LEE T, AIN K, REYNOLDS JC, ROBBINS J: Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J. Clin. Endocrinol. Metab. (1995) 80 5):1488-1492.
27. SCHLUMBERGER M, MANCUSI F, BAUDIN E, PACINI F: 131I therapy for elevated thyroglobulin levels. Thyroid(1997) 7 2):273-276.
28. BOMBARDIERI E, SEREGNI E, VILLANO C, ALIBERTI G, MATTAVELLI F: Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer. Tumori (2003) 89(5 ):533-536.
29. DAVID A, BLOTTA A, BONDANELLI M et al.: Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J. Nucl. Med. (2001) 42(10):1470-1475.
30. MCDOUGALL IR, WEIGEL RJ: Recombinant human thyrotropin in the management of thyroid cancer. Curr. Opin. Oncol. (2001) 13 1):39-43.
31. ROBBINS RJ, ROBBINS AK: Clinical review 156: recombinant human thyrotropin and thyroid cancer management. J. Clin. Endocrinol. Metab. (2003) 88(5):1933-1938.
32. GIOVANNI V, ARIANNA LG, ANTONIO C et al.: The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin. Endocrinol. (Oxf) (2002) 56(2):247-252.
33. HAUGEN BR, RIDGWAY EC, MCLAUGHLIN BA, MCDERMOTT MT: Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid (2002) 12(1):37-43.
34. MARIANI G, FERDEGHINI M, AUGERI C et al.: Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother. Radiopharm. (2000) 15(2):211-217.
35. PACINI F, MOLINARO E, LIPPI F et al.: Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. (2001) 86(12):5686-5690.
36. MAZZAFERRI EL, KLOOS RT: Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J. Clin. Endocrinol. Metab. (2002) 87(4):1490-1498.
37. MAZZAFERRI EL, ROBBINS RJ, SPENCER CA et al.: A consensus report of the role of serum thyroglobutin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. (2003) 88(4):1433-1441.
38. PACINI F, MOLINARO E, CASTAGNA MG et al.: Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. (2003) 88 8):3668-3673.
39. WOODMANSEE WW, HAUGEN BR: A review of the potential uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin. Endocrinol. (Oxf) (2004) 61(2):163-173.
40. SPENCER CA, TAKEUCHI M, KAZAROSYAN M et al.: Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. (1998) 83(4):1121-1127.
41. PETRICH T, BORNER AR, OTTO D, HOFMANN M, KNAPP WH: Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging (2002) 29 5):641-647.
42. CHIN BB, PATEL P, COHADE C, EWERTZ M, WAHL R, LADENSON P: Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. (2004) 89(1):91-95.
43. CORSETTI F, CHIANELLI M, CORNELISSEN B et al.: Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection. Cancer Biother. Radiopharm. (2004) 19(1):57-63.
44. PARK SG, REYNOLDS JC, BRUCKER-DAVIS F et al.: Iodine kinetics during 131-I scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) versus hypothyroidism. J. Nucl. Med. (1996) 37:15p (Abstract).
45. MAXON HR, THOMAS SR, HERTZBERG V et al.: Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N. Engl. J. Med. (1983) 309(16):937-941.
46. MAXON HR, THOMAS SR, SAMARATUNGA RC: Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid (1997) 7(2):183-187.
47. MENZEL C, KRANERT WT, DOBERT N et al.: rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. J. Nucl. Med. (2003) 44 7):1065-1068.
48. DE KEIZER B, BRANS B, HOEKSTRA A et al.: Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur. J. Nucl. Med. Mol. Imaging. (2003) 30(3):367-373.
49. PACINI F, MOLINARO E, CASTAGNA MG et al.: Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. (2002) 87 9):4063-4068.
50. BARBARO D, BONI G, MEUCCI G et al.: Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J. Clin. Endocrinol. Metab. (2003) 88(9 ):4110-4115.
51. BERG G, LINDSTEDT G, SUURKULA M, JANSSON S: Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J. Endocrinol. Invest. (2002) 25(1):44-52.
52. PELLEGRITI G, SCOLLO C, GIUFFRIDA D, VIGNERI R, SQUATRITO S, PEZZINO V: Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid (2001) 11(11):1025-1030.
53. LUSTER M, REINHARDT W, KORBER C et al.: The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J. Endocrinol. Invest. (2000) 23(7):473-475.
54. LUSTER M, LASSMANN M, HAENSCHEID H, MICHALOWSKI U, INCERTI C, REINERS C: Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. (2000) 85(10):3640-3645.
55. ROBBINS RJ, VOELKER E, WANG W, MACAPINLA C HA, LARSON SM: Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy-case report and review of literature. Endocr. Pract. (2000) 6(6):460-464.
56. LIPPI F, CAPEZZONE M, ANGELINI F et al.: Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur. J. Endocrinol. (2001) 144(1):5-11.
57. VARGAS GE, UY H, BAZAN C, GUISE TA, BRUDER JM: Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J. Clin. Endocrinol. Metab. (1999) 84 11):3867-3871.
58. GOFFMAN T, IOFFE V, TUTTLE M, BOWERS JT, MASON ME: Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma. Thyroid (2003) 13(8):827-830.
59. HEGEDUS L, BONNEMA SJ, BENNEDBAEK FN: Management of simple nodular goiter: current status and future perspectives. Endocr. Rev. (2003) 24(1):102-132.
60. MANDERS JM, CORSTENS FH: Radioiodine therapy of euthyroid multinodular goitres. Eur. J. Nucl. Med. Mol. Imaging (2002) 29 Suppl. 2):S466-S470.
61. NYGAARD B, HEGEDUS L, GERVIL M, HJALGRIM H, SOE-JENSEN P, HANSEN JM: Radioiodine treatment of multinodular non-toxic goitre. Br. Med. J. (1993) 307(6908):828-832.
62. HUYSMANS DA, HERMUS AR, CORSTENS FH, BARENTSZ JO, KLOPPENBORG PW: Large, compressive goiters treated with radioiodine. Ann. Intern. Med. (1994) 121(10):757-762.
63. WESCHE MF, TIEL-V-BUUL MM, SMITS NJ, WIERSINGA WM: Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter. Eur. J. Endocrinol. (1995) 132(1):86-87.
64. HUYSMANS D, HERMUS A, EDELBROEK M, BARENTSZ J, CORSTENS F, KLOPPENBORG P: Radioiodine for nontoxic multinodular goiter. Thyroid (1997) 7(2):235-239.
65. HERMUS AR, HUYSMANS DA: Treatment of benign nodular thyroid disease. N. Engl. J. Med. (1998) 338(20):1438-1447.
66. HUYSMANS DA, BUIJS WC, VAN DE VEN MT et al.: Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters. J. Nucl. Med. (1996) 37(12):2072-2079.
67. HUYSMANS DA, NIEUWLAAT WA, ERDTSIECK RJ et al.: Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J. Clin. Endocrinol. Metab. (2000) 85(10 ):3592-3596.
68. NIEUWLAAT WA, HERMUS AR, SIVRO-PRNDELJ F, CORSTENS FH, HUYSMANS DA: Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J. Clin. Endocrinol. Metab. (2001) 86(11):5330-5336.
69. NIEUWLAAT WA, HUYSMANS DA, VAN DEN BOSCH HC et al.: Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J. Clin. Endocrinol. Metab. (2003) 88(7):3121-3129.
70. DUICK DS, BASKIN HJ: Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr. Pract. (2003) 9 3):204-209.
71. SILVA MN, RUBIO IG, ROMAO R et al.: Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin. Endocrinol. (Oxf) (2004) 60(3):300-308.
72. BONNEMA SJ, NIELSEN VE, HEGEDUS L: Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J. Clin. Endocrinol. Metab. (2003) 88(12):6113-6114; author reply 6114-6115.
73. NYGAARD B, FABER J, HEGEDUS L: Acute changes in thyroid volume and function following 131I therapy of multinodular goitre. Clin. Endocrinol. (Oxf) (1994) 41(6):715-718.
74. HUYSMANS AK, HERMUS RM, EDELBROEK MA et al.: Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid (1997) 7 4):535-539.
75. FAGLIA G, BITENSKY L, PINCHERA A et al.: Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced biological activity of immunoreactive thyrotropin. J. Clin. Endocrinol. Metab. (1979) 48(6):989-998.
76. WIENER R, UTIGER RD, LEW R, EMERSON CH: Age, sex, and serum thyrotropin concentrations in primary hypothyroidism. Acta Endocrinol. (Copenh.) (1991) 124(4):364-369.
77. PAPANICOLAOU DA: Euthyroid Sick Syndrome and the role of cytokines. Rev. Endocr. Metab. Disord. (2000) 1(1-2):43-48.
78. COLLAZOS J, IBARRA S, MAYO J: Thyroid hormones in HIV-infected patients in the highly active antiretroviral therapy era: evidence of an interrelation between the thyroid axis and the immune system. AIDS (2003) 17(5):763-765.
79. WARD DL, BING-YOU RG: Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr. Prart. (2001) 7(1 ):52-58.
80. PAPO T: Interferon-alpha and auto-immunity. Rev. Med. Interne (2002) 23(Suppl. 4):501s-510s.
81. FUGAZZOLA L, PERSANI L, MANNAVOLA D et al.: Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during L-thyroxine replacement. Clin. Endocrinol. (Oxf) (2003) 59(2):230-236.
82. SKARULIS MC: The use of recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Rev. Endocr. Metab. Disord. (2000) 1(3):147-154.
83. LEITOLF H, TONG KP, GROSSMANN M, WEINTRAUB BD, SZKUDLINSKI MW: Bioengineering of human thyrotropin superactive analogs by site-directed 'lysine-scanning' mutagenesis. Cooperative effects between peripheral loops. J. Biol. Chem. (2000) 275(35 :27457-27465.